Final Height in Patients With CAH

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-11

Study Completion Date

2020-09-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Congenital adrenal hyperplasia (CAH) is the most common inherited disorder in the adrenal gland in children. Growth is usually affected in CAH patients either due to the disease itself or treatment consequences.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Growth Hormone (GH) in Congenital Adrenal Hyperplasia

NCT03162172

Adrenal Hyperplasia, Congenital

COMPLETED

Linear Growth of Children With Congenital Adrenal Hyperplasia

NCT04087148

Congenital Adrenal Hyperplasia

UNKNOWN

Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH

NCT06449456

Congenital Adrenal Hyperplasia Exercise Capacity Physical Activity +1 more

COMPLETED

Adult Height Prediction in Congenital Adrenal Hyperplasia

NCT03162159

Congenital Adrenal Hyperplasia

COMPLETED

COrticosteroid in Congenital Adrenal Hyperplasia

NCT02552251

Congenital Adrenal Hyperplasia

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

CAH comprises a group of autosomal recessive disorders caused by a deficiency of one of five enzymes needed for the synthesis of cortisol leading to defect in cortisol synthesis with or without aldosterone deficiency and an increase in the production of adrenocorticotropic hormone through negative feedback.

The most common form is 21-hydroxylase deficiency (21OHD), which forms more than 90 % of the cases.

In classic CAH, 75% of the patients have the salt wasting (SW) and 25% have the non salt-wasting phenotype (NSW).There are no clinical signs at birth in male infants and in female patients, CAH is suspected shortly after birth if there is genital ambiguity, ranging from slight clitromegaly to complete masculinization with acceleration of growth and pubertal development.

The non-classic (late onset) form of CAH is a less severe form of 21OHD, and is diagnosed later in life.

Final height in early and late onset patients has been reported as diminished (Hauffa et al, 1997).This could be attributed to androgen excess or treatment with steroids. Androgen excess can occur at any age leading to accelerated growth, early epiphyseal closure and compromised final adult height.

Despite that all forms of CAH differ in their degree of enzymatic deficiency, they all represent a therapeutic challenge to pediatric endocrinologists attempting to optimize growth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Adrenal Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients having a documented history of classical CAH.

Exclusion Criteria

* Patients with non classical CAH.
* Patients treated with growth hormone.
* Chronic use of medications unrelated to CAH which may affect growth like immunosuppressive drugs like azathioprine and drugs that affect growth hormone release like octreotide, pegvisomant, bromocriptine and cabergoline.
* Other chronic diseases that may affect growth like heart disease, inflammatory bowel disease and renal disease.
* Other causes of adrenal insufficiency.

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No